Related Experiment Video
Updated: Feb 10, 2026

Long-term Culture of Human Breast Cancer Specimens and Their Analysis Using Optical Projection Tomography
Published on: July 29, 2011
The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis
Wu Ding1, Zhian Li, Caiyun Wang
1Department of Oncological Surgery, Shaoxing Second Hostipal Department of Nephrology, Shaoxing Second Hostipal Department of Surgery, Shaoxing Keqiao Women & Children's Hospital, Shaoxing, China University of Southern California, Los Angeles, CA.
Background:
Recently, several high-quality clinical randomized controlled trials (RCTs) have identified that cyclin-dependent kinases (CDKs) 4/6 inhibitors obtained a great safety and efficacy, which can be consequently applied as a combination therapy with letrozole or fulvestrant for women who had advanced breast cancer and progressed while receiving endocrine therapy. In this systemic review, we performed a meta-analysis to explore whether CDK4/6 inhibitors had a significantly benefit to treating hormone receptor-positive (HR-positive)/human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer.
Methods:
The data for meta-analysis were collected from MEDLINE, EMBASE, and Cochrane Library from January 1980 to December 2017, and eventually 3182 patients from 6 RCTs were included.
Results:
The result showed the CDK4/6 inhibitor group had a longer progression-free survival (PFS) (hazard ratio = 0.51; 95% confidence interval [CI], 0.46-0.57, P < .00001), a better objective response (risk rate = 1.53; 95% CI, 1.35-1.74, P < .00001), as well as a better clinical benefit response (risk rate = 1.29; 95% CI, 1.13-1.47, P = .0001). Besides, subgroup analyses of PFS according to stratification factors and other baseline characteristics confirmed a great performance of CDK4/6 inhibitors across the all subgroups. And sensitive analysis showed that all outcomes were stable except Finn 2014 trail.
Conclusion:
CDK4/6 inhibitors can significantly prolong the PFS and improve the objective response and clinical benefit response among the patients with HR-positive/ HER2-negative advanced breast cancer.
Insights
Cyclin-dependent kinases (CDKs) 4/6 inhibitors significantly benefit patients with advanced hormone receptor-positive/HER2-negative breast cancer. This meta-analysis confirms improved progression-free survival and response rates with CDK4/6 inhibitor combination therapy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Recent randomized controlled trials (RCTs) demonstrate the safety and efficacy of cyclin-dependent kinases (CDKs) 4/6 inhibitors.
- These inhibitors are used in combination therapy with letrozole or fulvestrant for advanced breast cancer patients progressing on endocrine therapy.
Purpose of the Study:
- To conduct a meta-analysis evaluating the benefits of CDK4/6 inhibitors in treating hormone receptor-positive (HR-positive)/human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer.
Main Methods:
- Systematic review and meta-analysis of data from MEDLINE, EMBASE, and Cochrane Library (January 1980–December 2017).
- Included data from 6 RCTs involving 3182 patients.
Main Results:
- CDK4/6 inhibitor group showed significantly longer progression-free survival (PFS) (hazard ratio = 0.51; P < .00001).
- Improved objective response (risk rate = 1.53; P < .00001) and clinical benefit response (risk rate = 1.29; P = .0001) were observed.
- Subgroup and sensitive analyses confirmed consistent benefits across subgroups, with stability in outcomes.
Conclusions:
- CDK4/6 inhibitors significantly improve PFS in patients with HR-positive/HER2-negative advanced breast cancer.
- These inhibitors enhance objective response and clinical benefit response in the studied patient population.
More Related Videos
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Sample Preparation for Analysis: Advanced Techniques
Acid digestion with strong acids is commonly used to dissolve inorganic materials that are insoluble (do not dissolve) in water. This method can be useful for...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Random and Systematic Errors
Directing Effect of Substituents: meta-Directing Groups

